- Policy
- Kymriah's price negotiation has rarely been concluded
- by Lee, Jeong-Hwan Mar 17, 2022 05:58am
- Two months after passing the Drug Benefit Evaluation Committee, negotiations on drug prices for acute lymphocytic leukemia and lymphoma CAR-T treatments have rarely been concluded. Leukemia patients are urging the NHIS and Novartis Korea to strengthen Kymriah's access to patients with rapid drug price negotiations. On the 15th, Korea Leuke
- Policy
- Expectations on Yoon Seok Yeol's government
- by Lee, Jeong-Hwan Mar 16, 2022 05:57am
- Expectations are growing for the Yoon Seok-yeol administration's policy to quickly register and expand benefits for ultra-high-priced medicines such as anticancer drugs and rare incurable disease drugs. This is the effect of Yoon Seok-yeol, the elected president of the People's Power, making a pledge to quickly register severe diseases and rare
- Policy
- Price of desvenlafaxine IMDs to be discounted up to 10%
- by Lee, Tak-Sun Mar 16, 2022 05:57am
- The price of the follow-on drugs of the anti-depressant ‘desvenlafaxine’ that had been listed at 90% of the price of its original by avoiding the original’s patent through salt alterations have fallen greatly after a year and a half due to the adjustment of the price cap that was conducted following an investigation into their actual tran
- Policy
- HPV vaccine, which costs 600,000 won, free of charge ?
- by Lee, Jeong-Hwan Mar 16, 2022 05:57am
- Human papilloma virus (HPV) vaccine, which costs about 200,000 won per inoculation and 600,000 won per inoculation, is expected to do well in the health insurance coverage of room 9. It is the gate that President-elect Yoon Seok-yeol promised to expand the insurance of Gadasil 9 as a life-friendly pledge. Looking at the 13th "59-second sho
- Policy
- The government will begin to establish an Asian vaccine fund
- by Lee, Jeong-Hwan Mar 15, 2022 05:58am
- The government will review the need for joint vaccine purchase funds in Asia and start working on creating grounds for establishment. The move is aimed at preventing repeated cases of global difficulties in supplying vaccines with COVID-19 Pandemic and bridging the gap in accessibility to public vaccines and biopharmaceuticals by country.
- Policy
- RET mutant target anticancer drug has been approved
- by Lee, Tak-Sun Mar 15, 2022 05:57am
- For the first time in Korea, a new anticancer drug targeting a REarranged during Transfection (RET) mutation has been approved. RET is a phosphorylation enzyme that can cause cancer and is known to promote the proliferation of cancer cells when mutated or combined with other genes. The MFDS approved "Retevmo Capsule 40·80mg (Selpercatinib
- Policy
- Yoon Seok-yeol was elected president
- by Lee, Jeong-Hwan Mar 15, 2022 05:57am
- Attention is focusing on the pledge to establish a global vaccine hub and quickly register health insurance for severe treatments. In the 20th presidential election, Yoon Seok-yeol, the power of the people, was confirmed to win the election, beating Lee Jae-myung of the Democratic Party of Korea. Candidate Yoon Seok-yeol won 48.56% (16,394,81
- Policy
- Yoon Seok-yeol expands R&D for telemedicine & bio
- by Lee, Jeong-Hwan Mar 14, 2022 05:51am
- After the inauguration of the Yoon Seok-yeol administration, legal experts analyzed that the biohealth industry policy paradigm will shift, such as expanding digital healthcare and strengthening government R&D support in advanced medical fields of vaccines and treatments. It is predicted that the biohealth sector will be transformed compar
- Policy
- P3T for Sarepta’s DMD treatment approved in Korea
- by Lee, Hye-Kyung Mar 14, 2022 05:51am
- A Phase III trial for the Duchenne muscular dystrophy treatment 'SRP-4045(casimersen)’ and 'SRP-4053 (golodirsen)' will be conducted in Korea. The Ministry of Food and Drug Safety has recently approved Ppdd Velllovement Pte Ltd’s application for the double-blind, placebo-controlled, multicenter clinical trial to evaluate Sarepta Therap
- Policy
- Securing Paxlovid's inventory for 120,000 people
- by Lee, Jeong-Hwan Mar 14, 2022 05:50am
- Paxlovid's inventory in Korea is about 120,000 people, it said on the 11th. The response is to the point that there is no shortage of prescriptions for confirmed patients, which has been on the rise recently, and that there is no inventory of Paxlovid at front-line pharmacies or medical sites. More and more patients want Paxlovid due to th
